Ironwood Pharmaceuticals Stock Buy Hold or Sell Recommendation
| IRWD Stock | USD 3.34 0.18 5.11% |
Given the investment horizon of 90 days and your conservative attitude towards risk, our recommendation regarding Ironwood Pharmaceuticals is 'Strong Sell'. Macroaxis provides Ironwood Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IRWD positions.
Check out Ironwood Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide. Note, we conduct extensive research on individual companies such as Ironwood and provide practical buy, sell, or hold advice based on investors' constraints. Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
Ironwood |
Execute Ironwood Pharmaceuticals Buy or Sell Advice
The Ironwood recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Ironwood Pharmaceuticals. Macroaxis does not own or have any residual interests in Ironwood Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ironwood Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Ironwood Pharmaceuticals Trading Alerts and Improvement Suggestions
| Ironwood Pharmaceuticals generated a negative expected return over the last 90 days | |
| Ironwood Pharmaceuticals has high historical volatility and very poor performance | |
| Ironwood Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Ironwood Pharmaceuticals SVP sells shares for 44,884 |
Ironwood Pharmaceuticals Returns Distribution Density
The distribution of Ironwood Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Ironwood Pharmaceuticals' future price movements. The chart of the probability distribution of Ironwood Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Ironwood Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ironwood Pharmaceuticals returns is essential to provide solid investment advice for Ironwood Pharmaceuticals.
| Mean Return | -0.36 | Value At Risk | -7.54 | Potential Upside | 6.62 | Standard Deviation | 4.42 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ironwood Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ironwood Stock Institutional Investors
| Shares | Kynam Capital Management, Lp | 2024-09-30 | 3.7 M | Geode Capital Management, Llc | 2024-06-30 | 3.4 M | Man Group Plc | 2024-06-30 | 3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.9 M | Jpmorgan Chase & Co | 2024-06-30 | 1.9 M | Ubs Group Ag | 2024-06-30 | 1.8 M | Amvescap Plc. | 2024-06-30 | 1.7 M | Goldman Sachs Group Inc | 2024-06-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Blackrock Inc | 2024-06-30 | 22.9 M | Vanguard Group Inc | 2024-09-30 | 22 M |
Ironwood Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.6M) | 185.5M | 257.1M | 36.1M | (565.8M) | (537.5M) | |
| Free Cash Flow | 3.5M | 167.0M | 261.6M | 273.6M | 183.2M | 192.3M | |
| Depreciation | 5.6M | 3.6M | 1.5M | 1.4M | 1.6M | 1.5M | |
| Other Non Cash Items | 16.4M | 22.3M | 25.2M | 1.7M | 1.1B | 1.1B | |
| Capital Expenditures | 7.2M | 1.8M | 265K | 136K | 273K | 259.4K | |
| Net Income | 21.5M | 106.2M | 528.4M | 175.1M | (1.0B) | (952.1M) | |
| End Period Cash Flow | 179.2M | 364.8M | 621.9M | 657.9M | 92.2M | 87.5M | |
| Investments | (11.1M) | (1.8M) | (265K) | (136K) | (1.0B) | (971.0M) | |
| Change Receivables | (68.9M) | 4.1M | 7.7M | 8.0M | 9.2M | 9.7M | |
| Net Borrowings | 8.5M | (1.8M) | 16.3M | (120.7M) | (108.6M) | (103.2M) | |
| Change To Netincome | 90.0M | 19.5M | (321.7M) | 91.5M | 82.3M | 86.5M |
Ironwood Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ironwood Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ironwood Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ironwood stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.62 | |
β | Beta against Dow Jones | 2.92 | |
σ | Overall volatility | 4.37 | |
Ir | Information ratio | -0.1 |
Ironwood Pharmaceuticals Volatility Alert
Ironwood Pharmaceuticals exhibits very low volatility with skewness of 0.17 and kurtosis of 0.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ironwood Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ironwood Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Ironwood Pharmaceuticals Fundamentals Vs Peers
Comparing Ironwood Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ironwood Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Ironwood Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ironwood Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Ironwood Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ironwood Pharmaceuticals to competition |
| Fundamentals | Ironwood Pharmaceuticals | Peer Average |
| Return On Equity | -5.75 | -0.31 |
| Return On Asset | 0.13 | -0.14 |
| Profit Margin | (0.01) % | (1.27) % |
| Operating Margin | 0.28 % | (5.51) % |
| Current Valuation | 1.09 B | 16.62 B |
| Shares Outstanding | 160.03 M | 571.82 M |
| Shares Owned By Insiders | 1.68 % | 10.09 % |
| Shares Owned By Institutions | 98.32 % | 39.21 % |
| Number Of Shares Shorted | 10.96 M | 4.71 M |
| Price To Earning | 18.35 X | 28.72 X |
| Price To Book | 2.59 X | 9.51 X |
| Price To Sales | 1.49 X | 11.42 X |
| Revenue | 442.74 M | 9.43 B |
| Gross Profit | 366.33 M | 27.38 B |
| EBITDA | (924.86 M) | 3.9 B |
| Net Income | (1 B) | 570.98 M |
| Cash And Equivalents | 504.36 M | 2.7 B |
| Cash Per Share | 3.29 X | 5.01 X |
| Total Debt | 715.54 M | 5.32 B |
| Debt To Equity | 0.78 % | 48.70 % |
| Current Ratio | 26.52 X | 2.16 X |
| Book Value Per Share | (1.95) X | 1.93 K |
| Cash Flow From Operations | 183.43 M | 971.22 M |
| Short Ratio | 8.94 X | 4.00 X |
| Earnings Per Share | (0.01) X | 3.12 X |
| Price To Earnings To Growth | (0.26) X | 4.89 X |
| Target Price | 12.5 | |
| Number Of Employees | 267 | 18.84 K |
| Beta | 0.48 | -0.15 |
| Market Capitalization | 563.3 M | 19.03 B |
| Total Asset | 471.07 M | 29.47 B |
| Retained Earnings | (1.7 B) | 9.33 B |
| Working Capital | (42.81 M) | 1.48 B |
Note: Disposition of 11001 shares by Sravan Emany of Ironwood Pharmaceuticals at 4.08 subject to Rule 16b-3 [view details]
Ironwood Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ironwood . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 3.34 | |||
| Day Typical Price | 3.34 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.18) | |||
| Relative Strength Index | 43.64 |
About Ironwood Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Ironwood Pharmaceuticals? Buying financial instruments such as Ironwood Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ironwood Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Transportation Thematic Idea Now
Transportation
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Transportation theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Transportation Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ironwood Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.